Insiders Annexon, Inc.

Equities

ANNX

US03589W1027

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
4.795 ^USD	+5.04%		-0.52%	+5.62%

Jun. 25	Annexon Reports 'Positive' Results From Phase 3 Study of Guillain-Barre Syndrome	MT
Jun. 25	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting	CI

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Annexon Insider Bought Shares Worth $1,008,000, According to a Recent SEC Filing	Dec. 28	MT
Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer	23-07-31	CI
Annexon Names Dean Artis Chief Scientific Officer	23-01-06	MT
Annexon, Inc. Announces Executive Changes	23-01-06	CI
Insider Buy: Annexon	22-07-12	MT
Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer	22-02-22	CI
Annexon, Inc. Announces Resignation of Ricky Sun as Board Member	22-02-03	CI
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to Its Board of Directors	22-01-20	CI
Annexon, Inc. Announces Executive Appointments	21-10-04	CI
Annexon : Names Larry Mattheakis as Chief Scientific Officer	21-10-04	MT
Annexon Appoints Will Waddill to Its Board of Directors	21-08-16	CI
Annexon, Inc. Announces Executive Changes	21-03-01	CI
Annexon, Inc. Announces Executive Changes	21-02-08	CI
Annexon, Inc. Appoints Michael Overdorf as Chief Business Officer	20-07-30	CI
Annexon Biosciences Announces Board Appointments	17-03-09	CI
Annexon Biosciences Announces Executive Appointments	16-01-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Secure my Investments

fermer